LeMaitre Vascular (NASDAQ:LMAT) Updates Q3 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its third quarter 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 0.420-0.460 for the period, compared to the consensus earnings per share estimate of 0.420. The company issued revenue guidance of $52.7 million-$54.7 million, compared to the consensus revenue estimate of $52.4 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.820-1.910 EPS.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Roth Mkm reiterated a buy rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Roth Capital upgraded LeMaitre Vascular to a strong-buy rating in a report on Friday, May 31st. JMP Securities increased their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research note on Friday, May 3rd. StockNews.com lowered LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday. Finally, Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday. They set a buy rating and a $105.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of Moderate Buy and an average target price of $83.71.

LeMaitre Vascular Stock Performance

LMAT stock traded down $1.24 during mid-day trading on Friday, reaching $85.01. The company had a trading volume of 348,354 shares, compared to its average volume of 157,693. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 56.30, a price-to-earnings-growth ratio of 2.63 and a beta of 0.89. The firm has a fifty day simple moving average of $82.69 and a 200 day simple moving average of $71.68. LeMaitre Vascular has a fifty-two week low of $44.27 and a fifty-two week high of $91.76.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. LeMaitre Vascular’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.37 EPS. As a group, analysts predict that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the sale, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO George W. Lemaitre sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the sale, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold 127,437 shares of company stock valued at $10,076,242 in the last quarter. Corporate insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.